WebProlastin replacement therapy, 60 mg/kg body w eight, once weekly for up to 26 weeks (average 24 weeks of therapy). With this schedule of replacement therapy, blood levels of alpha WebThe five approved products are Prolastin-C® and Prolastin-C Liquid® from Grifols, Aralast NP™ from Takeda, Zemaira® from CSL Behring and Glassia® from Takeda. A product named Trypsone® from Grifols is available in Spain. Prolastin has been marketed since 1988 and has an excellent safety record.

PROLASTIN®-C Liquid for Alpha1-Antitrypsin Deficiency

WebHere, we describe the design of the ongoing Study of ProlAstin-c Randomized Therapy with Alpha-1 augmentation (SPARTA), a phase 3 trial designed to evaluate progression of lung … WebJan 22, 2024 · Grifols developed Lynspad™ (sold as Prolastin-C ® in other markets) and designated OrphanPacific as the Appointed Marketing Authorization Holder (AMAH) to obtain manufacturing and marketing approval for the AATD treatment in Japan under the Foreign Exceptional Approval System, an approach for a company intending to … fratelli\u0027s in middletown md

Grifols increases its revenues to 5,340 M€ and continues …

WebMay 22, 2013 · Grifols is using data from the SPARK study as the basis to proceed with a larger, long-term study of the two doses of PROLASTIN-C. The trial, known as SPARTA, will be the first and only... WebFeb 26, 2024 · The company continued to enhance its portfolio in 2024, integrating new products and presentations, including the FDA-approved Prolastin ® -C Liquid in 0.5-gram … WebAbout Grifols Products Transfusion Medicine Blood Typing Conventional Serology Reagents Antisera Product Specifications Antisera portfolio for US and Canada Antisera portfolio for US and Canada Grifols extensive line of monoclonal antisera for the detection of Rh and rare antigens offer blood banks lower turnaround time and decreased workflow. fratelli\u0027s in thurmont md